After completion of his Ph.D research in Medical Biochemistry from Madras University, India, Peramaiyan Rajendran joined NPO Int. Lab. Biochemistry in Japan, and NUS in Singapore. He worked in the area of diabetes and cancer research for his post-doctoral studies. Later, he joined China Medical University Taiwan in 2016 as a postdoctoral fellow. Currently, he is working as an assistant professor at King Faisal University, Saudi Arabia.
The focus of his research over the past few years has been to elucidate the mechanism(s) of activation of molecular signaling carcinogens and inflammatory agents and the identification of novel inhibitors for the prevention of and therapy for cancer. Thus, these agents have potential treatment properties for numerous inflammatory diseases, including cancer, and are not toxic. Moreover, the results his research work have so far led to hundreds of scientific publications in high impact peer reviewed journals and several international research awards.
After completion of his Ph.D research in Medical Biochemistry from Madras University, India, Peramaiyan Rajendran joined NPO Int. Lab. Biochemistry in Japan, and NUS in Singapore. He worked in the area of diabetes and cancer research for his post-doctoral studies. Later, he joined China Medical University Taiwan in 2016 as a postdoctoral fellow. Currently, he is working as an assistant professor at King Faisal University, Saudi Arabia.
The focus of his research over the past few years has been to elucidate the mechanism(s) of activation of molecular signaling carcinogens and inflammatory agents and the identification of novel inhibitors for the prevention of and therapy for cancer. Thus, these agents have potential treatment properties for numerous inflammatory diseases, including cancer, and are not toxic. Moreover, the results his research work have so far led to hundreds of scientific publications in high impact peer reviewed journals and several international research awards.